Compare HLX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | OGN |
|---|---|---|
| Founded | 1979 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | HLX | OGN |
|---|---|---|
| Price | $9.80 | $13.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $11.50 | $11.40 |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $876,561,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $2.05 | $0.45 |
| Revenue Next Year | $5.46 | $1.67 |
| P/E Ratio | ★ N/A | $24.58 |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.58 | $5.69 |
| 52 Week High | $10.75 | $13.60 |
| Indicator | HLX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 60.43 |
| Support Level | $9.21 | $13.46 |
| Resistance Level | $9.89 | $13.60 |
| Average True Range (ATR) | 0.28 | 0.03 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 92.16 | 54.17 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.